drugset / Trial / NCT06291987
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this research is to gather information on the safety and effectiveness determining maximum tolerated dose (MTD) of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs while evaluate the efficacy of ruxolitinib in combination with ivosidenib in IDH1-mutated advanced-phase Ph-negative MPNs.
Timeline
- Start
- 2024-09-19
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivosidenib | Small molecule | 500 mg | — |
| Subject | Ruxolitinib | Small molecule | 5 mg | — |
| Subject | Ruxolitinib | Small molecule | 10 mg | — |
| Subject | Ruxolitinib | Small molecule | 20 mg | — |